Cargando…

Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.

Camptothecins are DNA topoisomerase I-directed anti-tumour drugs with a novel mechanism of action. Topotecan (TPT), a hydrophilic derivative of camptothecin, is currently undergoing phase II clinical trials in small-cell lung cancer (SCLC). Human SCLC OC-NYH cells were made more than 6-fold resistan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sorensen, M., Sehested, M., Jensen, P. B.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1995
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034011/ https://www.ncbi.nlm.nih.gov/pubmed/7640225

Ejemplares similares

Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.
por: Sorensen, M., et al.
Publicado: (1998)

In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
por: Jensen, P. B., et al.
Publicado: (1997)

Structural and Dynamical Effects Induced by the Anticancer Drug Topotecan on the Human Topoisomerase I – DNA Complex
por: Mancini, Giordano, et al.
Publicado: (2010)

Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells
por: Jensen, Lars H, et al.
Publicado: (2004)

Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.
por: Kreisholt, J., et al.
Publicado: (1998)

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
por: Schellens, J. H., et al.
Publicado: (1996)

Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer
por: Lv, Chunxin, et al.
Publicado: (2018)

Topoisomerase I Inhibitors, Shikonin and Topotecan, Inhibit Growth and Induce Apoptosis of Glioma Cells and Glioma Stem Cells
por: Zhang, Feng-Lei, et al.
Publicado: (2013)

Three different mutations in the DNA topoisomerase 1B in Leishmania infantum contribute to resistance to antitumor drug topotecan
por: Rosa-Teijeiro, Chloé, et al.
Publicado: (2021)

New 5-Hydroxycoumarin-Based Tyrosyl-DNA Phosphodiesterase I Inhibitors Sensitize Tumor Cell Line to Topotecan
por: Khomenko, Tatyana M., et al.
Publicado: (2023)

DNA topoisomerase I and II expression in drug resistantgerm cell tumours
por: Berney, D M, et al.
Publicado: (2002)

Topotecan in the treatment of relapsed small cell lung cancer
por: Quoix, Elisabeth
Publicado: (2008)

Small DNA circles as bacterial topoisomerase I inhibitors
por: Li, Dawei, et al.
Publicado: (2019)

Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study
por: Aktas, Gokmen, et al.
Publicado: (2016)

Topotecan: An evolving option in the treatment of relapsed small cell lung cancer
por: Garst, Jennifer
Publicado: (2007)

Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer
por: Riemsma, Rob, et al.
Publicado: (2010)

Anti-DNA topoisomerase I autoantibodies bind directly to the cell surface of fibroblasts in patients with systemic sclerosis
por: Senécal, J-L, et al.
Publicado: (2004)

Myotilin, a New Topotecan Resistant Protein in Ovarian Cancer Cell Lines
por: Sterzyńska, Karolina, et al.
Publicado: (2018)

Enhanced Topoisomerase I Activity and Increased Topoisomerase IIα Content in Cisplatin‐resistant Cancer Cell Lines
por: Minagawa, Yukihisa, et al.
Publicado: (1997)

A phase I and pharmacokinetic study of intraperitoneal topotecan
por: Hofstra, L S, et al.
Publicado: (2001)

Evodiamine Stabilizes Topoisomerase I-DNA Cleavable Complex to Inhibit Topoisomerase I Activity
por: Chan, Agnes L.-F., et al.
Publicado: (2009)

On the viability of Escherichia coli cells lacking DNA topoisomerase I
por: Stockum, Anna, et al.
Publicado: (2012)

The modulation of topoisomerase I-mediated DNA cleavage and the induction of DNA–topoisomerase I crosslinks by crotonaldehyde-derived DNA adducts
por: Dexheimer, Thomas S., et al.
Publicado: (2008)

Role of Topotecan in Non-Small Cell Lung Cancer: A Review of Literature
por: Vennepureddy, Adarsh, et al.
Publicado: (2015)

Establishment and Characterization of a Topotecan Resistant Non-small Cell Lung Cancer NCI-H460/TPT10 Cell Line
por: Lei, Zi-Ning, et al.
Publicado: (2020)

Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines
por: Moisan, F, et al.
Publicado: (2006)

Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.
por: Jensen, P. B., et al.
Publicado: (1993)

Topotecan or other agents as second-line therapy for relapsed small-cell lung cancer: A meta-analysis of randomized studies
por: Petrelli, Fausto, et al.
Publicado: (2021)

Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.
por: Jonsson, E., et al.
Publicado: (1997)

Adverse drug reaction after intravitreal injection of topotecan
por: Narang, Subina, et al.
Publicado: (2020)

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
por: Ando, M., et al.
Publicado: (1997)

Bacterial topoisomerase I and topoisomerase III relax supercoiled DNA via distinct pathways
por: Terekhova, Ksenia, et al.
Publicado: (2012)

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.
por: Herben, V. M., et al.
Publicado: (1997)

Gene Mutation Analysis and Quantitation of DNA Topoisomerase I in Previously Untreated Non‐small Cell Lung Carcinomas
por: Takatani, Hiroshi, et al.
Publicado: (1997)

The Lipophilic Purine Nucleoside—Tdp1 Inhibitor—Enhances DNA Damage Induced by Topotecan In Vitro and Potentiates the Antitumor Effect of Topotecan In Vivo
por: Chernyshova, Irina A., et al.
Publicado: (2022)

Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy.
por: Mainwaring, P. N., et al.
Publicado: (1997)

N-terminal domain of tyrosyl-DNA phosphodiesterase I regulates topoisomerase I-induced toxicity in cells
por: Brettrager, Evan J., et al.
Publicado: (2023)

The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Doxorubicin and Topotecan Resistant Ovarian Cancer Cell Lines
por: Stasiak, Piotr, et al.
Publicado: (2022)

DNA topoisomerases as molecular targets for anticancer drugs
por: Buzun, Kamila, et al.
Publicado: (2020)

Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients
por: Horita, Nobuyuki, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v17dn32jmlp9ipj6m2til56bp7